RxDoctor Payments Data

Joshua Vera, PA

Physician Assistant · Turlock, CANPI 1346530029

Payments from drug & device makers

$2,949in general payments, 2019–2025

Across 158 payments — averaging $18.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$415
  • Lilly USA, LLC$380
  • AbbVie$375
  • Sanofi$307
  • Incyte Corporation$302
  • Regeneron Healthcare Solutions, Inc.$264
  • plus $907 from 10 others

What the payments were for

  • Food & beverage$2,78194%
  • Education$1686%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,949 in reported general payments places this provider in the 85th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$493,895
Medicare patients
697
Services billed
7,148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TremfyaGuselkumab12$154,147
Dupixent PenDupilumab40$136,670
Cosentyx Sensoready (2 Pens)Secukinumab19$135,506
Ketoconazole294$7,388
Clobetasol Propionate186$6,182
Calcipotriene22$5,658
Tacrolimus35$4,517
Fluorouracil57$3,731
Fluocinonide55$2,835
Mometasone Furoate124$2,757
Azelaic Acid24$2,538
Desonide56$2,457
Tretinoin27$2,165
Gentamicin Sulfate45$1,729
Metronidazole20$1,500

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$415$154,14712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Turlock

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →